Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × Magnetic Resonance Spectroscopy × Clear all

NCT04071236 2026-03-18

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT05888532 2026-03-17

64Cu-GRIP B in Patients With Advanced Malignancies

Phase 1/2 Recruiting

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT02555189 2024-05-13

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Completed

Prostatic Neoplasms

NCT02488070 2018-03-20

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Phase 1/2 Completed

10 enrolled 8 charts

Prostatic Neoplasms